Medpace Holdings, Inc. $MEDP Shares Purchased by Ethic Inc.

Ethic Inc. boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 199.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,324 shares of the company’s stock after purchasing an additional 1,547 shares during the quarter. Ethic Inc.’s holdings in Medpace were worth $692,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Liontrust Investment Partners LLP acquired a new stake in Medpace during the first quarter worth about $557,000. LGT Group Foundation acquired a new stake in Medpace during the first quarter worth about $682,000. Russell Investments Group Ltd. increased its stake in Medpace by 118.7% during the first quarter. Russell Investments Group Ltd. now owns 68,973 shares of the company’s stock worth $21,016,000 after acquiring an additional 37,442 shares during the last quarter. HighTower Advisors LLC increased its stake in Medpace by 1.5% during the first quarter. HighTower Advisors LLC now owns 3,188 shares of the company’s stock worth $971,000 after acquiring an additional 48 shares during the last quarter. Finally, Enhancing Capital LLC increased its stake in Medpace by 3.4% during the first quarter. Enhancing Capital LLC now owns 1,483 shares of the company’s stock worth $452,000 after acquiring an additional 49 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares in the company, valued at $4,654,350. The trade was a 22.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 48,487 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the completion of the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at approximately $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 112,788 shares of company stock valued at $51,018,354. Company insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on MEDP. Mizuho upped their price target on Medpace from $328.00 to $510.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Truist Financial upped their price target on Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a research note on Wednesday, July 23rd. William Blair restated a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. Barclays upped their price target on Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research note on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace presently has an average rating of “Reduce” and an average target price of $406.60.

Medpace Stock Performance

MEDP stock opened at $465.72 on Thursday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $501.30. The firm has a market cap of $13.08 billion, a P/E ratio of 34.63, a price-to-earnings-growth ratio of 2.91 and a beta of 1.42. The stock has a 50-day simple moving average of $372.56 and a 200-day simple moving average of $333.62.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. During the same quarter last year, the firm earned $2.75 earnings per share. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.